In R/R Hodgkin lymphoma, CD30-directed CAR T-cell therapy showed a manageable safety profile and significant activity in phase I clinical trials, employing either CD30-BBz (202) or CD30-28z CAR T-cell products (203), especially after lymphodepleting chemotherapy was introduced (204). Here, TNFRSF8 is linked to Hodgkins lymphoma.